{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:26:03Z","timestamp":1780579563771,"version":"3.54.1"},"reference-count":312,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MEXT KAKENHI","award":["19K18846"],"award-info":[{"award-number":["19K18846"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ek0109458h0001"],"award-info":[{"award-number":["20ek0109458h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Retinopathy of prematurity (ROP), a vascular proliferative disease affecting preterm infants, is a leading cause of childhood blindness. Various studies have investigated the pathogenesis of ROP. Clinical experience indicates that oxygen levels are strongly correlated with ROP development, which led to the development of oxygen-induced retinopathy (OIR) as an animal model of ROP. OIR has been used extensively to investigate the molecular mechanisms underlying ROP and to evaluate the efficacy of new drug candidates. Large clinical trials have demonstrated the efficacy of anti-vascular endothelial growth factor (VEGF) agents to treat ROP, and anti-VEGF therapy is presently becoming the first-line treatment worldwide. Anti-VEGF therapy has advantages over conventional treatments, including being minimally invasive with a low risk of refractive error. However, long-term safety concerns and the risk of late recurrence limit this treatment. There is an unmet medical need for novel ROP therapies, which need to be addressed by safe and minimally invasive therapies. The recent progress in biotechnology has contributed greatly to translational research. In this review, we outline how basic ROP research has evolved with clinical experience and the subsequent emergence of new drugs. We discuss previous and ongoing trials and present the candidate molecules expected to become novel targets.<\/jats:p>","DOI":"10.3390\/jcm10020331","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T05:17:34Z","timestamp":1610947054000},"page":"331","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-8133","authenticated-orcid":false,"given":"Mitsuru","family":"Arima","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 8128582, Japan"},{"name":"Center for Clinical and Translational Research, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 8128582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 8128582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 8128582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"F179","DOI":"10.1136\/archdischild-2014-306207","article-title":"Impact of retinopathy of prematurity on ocular structures and visual functions","volume":"100","author":"Fielder","year":"2014","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum. Dev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e20153387","DOI":"10.1542\/peds.2015-3387","article-title":"Interventions to Prevent Retinopathy of Prematurity: A Meta-analysis","volume":"137","author":"Fang","year":"2016","journal-title":"Pediatrics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/jama.2015.10244","article-title":"Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993\u20132012","volume":"314","author":"Stoll","year":"2015","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","article-title":"Incidence and Early Course of Retlnonathy of Prematurity","volume":"98","author":"Palmer","year":"1991","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ophtha.2016.03.026","article-title":"Changes in course of retinopathy of prematurity from 1986 to 2013: Comparison of three studies in the United States","volume":"123","author":"Quinn","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1350-9462(01)00012-X","article-title":"Development of the Primate Retinal Vasculature","volume":"20","author":"Provis","year":"2001","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/archophthalmol.2012.2270","article-title":"Evaluation of Normal Human Foveal Development Using Optical Coherence Tomography and Histologic Examination","volume":"130","author":"Dubis","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.preteyeres.2009.06.003","article-title":"The neurovascular retina in retinopathy of prematurity","volume":"28","author":"Fulton","year":"2009","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1167\/iovs.06-1199","article-title":"A comparison of macular structure imaged by optical coherence tomog-raphy in preterm and full-term children","volume":"48","author":"Ecsedy","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1167\/iovs.07-1228","article-title":"Foveal Fine Structure in Retinopathy of Prematurity: An Adaptive Optics Fourier Domain Optical Coherence Tomography Study","volume":"49","author":"Hammer","year":"2008","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1167\/iovs.07-1226","article-title":"The Cone Electroretinogram in Retinopathy of Prematurity","volume":"49","author":"Fulton","year":"2008","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8340729-5","DOI":"10.1155\/2019\/8340729","article-title":"The Size of the Foveal Avascular Zone Is Associated with Foveal Thickness and Structure in Premature Children","volume":"2019","author":"Miki","year":"2019","journal-title":"J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1203\/PDR.0b013e31821764b1","article-title":"A Prospective Longitudinal Study to Estimate the \u201cAdjusted Cortisol Percentile\u201d in Preterm Infants","volume":"69","author":"Ng","year":"2011","journal-title":"Pediatr. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1203\/PDR.0b013e31816c8fcc","article-title":"Comparison of Serum Cortisol Concentrations in Preterm Infants with or Without Late-Onset Circulatory Collapse due to Adrenal Insufficiency of Prematurity","volume":"63","author":"Masumoto","year":"2008","journal-title":"Pediatr. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"F571","DOI":"10.1136\/archdischild-2016-311289","article-title":"Adrenocortical insufficiency and refractory hypotension in preterm infants","volume":"101","author":"Ng","year":"2016","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/IAE.0b013e31819a5fb1","article-title":"Must screening examinations for retinopathy of prematurity necessarily be painful?","volume":"29","author":"Kirchner","year":"2009","journal-title":"Retina"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1267","DOI":"10.1542\/peds.2006-2510","article-title":"Lower Stress Responses After Newborn Individualized Developmental Care and Assessment Program Care During Eye Screening Examinations for Retinopathy of Prematurity: A Randomized Study","volume":"121","author":"Kleberg","year":"2008","journal-title":"Pediatrics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-04269-5","article-title":"Late-onset Circulatory Collapse and Continuous Positive Airway Pressure are Useful Predictors of Treatment-requiring Retinopathy of Prematurity: A 9-year Retrospective Analysis","volume":"7","author":"Arima","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev.bioeng.4.020702.153438","article-title":"DNA Microarray Technology: Devices, Systems, and Applications","volume":"4","author":"Heller","year":"2002","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nbt0303-255","article-title":"Proteomic analysis of post-translational modifications","volume":"21","author":"Mann","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrg2934","article-title":"RNA sequencing: Advances, challenges and opportunities","volume":"12","author":"Ozsolak","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/ar700108g","article-title":"Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs","volume":"41","author":"Chari","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: Mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_26","first-page":"294","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nat. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert Panel Recommendations for the Use of Anti\u2013Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders","volume":"121","author":"Jabs","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/ICU.0b013e3282f0ca54","article-title":"Anti-vascular endothelial growth factor therapy for ocular neovascular disease","volume":"18","author":"Andreoli","year":"2007","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: A randomized clinical trial","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","article-title":"Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study","volume":"124","author":"Tadayoni","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_32","first-page":"764","article-title":"Prophylactic peripheral laser and fluorescein angiography afer bevacizumab for retinopathy of prematurity","volume":"38","author":"Snyder","year":"2017","journal-title":"Retina"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very Late Reactivation of Retinopathy of Prematurity After Monotherapy with Intravitreal Bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of Retinopathy of Prematurity Three Years After Treatment with Bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of Retinopathy of Prematurity After Bevacizumab Injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum Levels of Vascular Endothelial Growth Factor and Related Factors After Intravitreous Bevacizumab Injection for Retinopathy of Prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lien, R., Yu, M.-H., Hsu, K.-H., Liao, P.-J., Chen, Y.-P., Lai, C.-C., and Wu, W.-C. (2016). Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148019"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e20183537","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental Outcomes of Preterm Infants with Retinopathy of Prematurity by Treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Arima, M., Akiyama, M., Fujiwara, K., Mori, Y., Inoue, H., Seki, E., Nakama, T., Tsukamoto, S., Ochiai, M., and Ohga, S. (2020). Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230678"},{"key":"ref_41","first-page":"145","article-title":"Anti-VEGF for ROP and pediatric retinal diseases","volume":"7","author":"Wu","year":"2018","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamaophthalmol.2018.0376","article-title":"G-ROP Study Group Validation of the Colorado Retinopathy of Prematurity Screening Model","volume":"136","author":"McCourt","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2019.4502","article-title":"Individual risk prediction for sight-threatening retinopathy of prematurity using birth characteristics","volume":"138","author":"Pivodic","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.ophtha.2016.06.037","article-title":"Telemedicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity Cooperative Group Risk Score for Predicting Treatment-Requiring Retinopathy of Prematurity (ROP) in the Telemedicine Approaches to Evaluating Acute-Phase ROP Study","volume":"123","author":"Ying","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/archopht.124.12.1711","article-title":"Longitudinal Postnatal Weight and Insulin-like Growth Factor I Measurements in the Prediction of Retinopathy of Prematurity","volume":"124","author":"Andersson","year":"2006","journal-title":"Arch. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1542\/peds.2008-2697","article-title":"Early Weight Gain Predicts Retinopathy in Preterm Infants: New, Simple, Efficient Approach to Screening","volume":"123","author":"Niklasson","year":"2009","journal-title":"Pediatrics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/eye.2011.334","article-title":"A predictive score for retinopathy of prematurity in very low birth weight preterm infants","volume":"26","author":"Eckert","year":"2011","journal-title":"Eye"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/archophthalmol.2012.2524","article-title":"The CHOP Postnatal Weight Gain, Birth Weight, and Gestational Age Retinopathy of Prematurity Risk Model","volume":"130","author":"Binenbaum","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/bjophthalmol-2013-303123","article-title":"Reduction in screening for retinopathy of prematurity through risk factor adjusted inclusion criteria","volume":"97","author":"Kerkhoff","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Greenwald, M.F., Danford, I.D., Shahrawat, M., Ostmo, S., Brown, J., Kalpathy-Cramer, J., Bradshaw, K., Schelonka, R., Cohen, H.S., and Chan, R.V.P. (2020). Evaluation of artificial intelligence-based telemedicine screening for retinopathy of prematurity. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus, 160\u2013162.","DOI":"10.1016\/j.jaapos.2020.01.014"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/jamaophthalmol.2018.1934","article-title":"Automated Diagnosis of Plus Disease in Retinopathy of Prematurity Using Deep Convolutional Neural Networks","volume":"136","author":"Brown","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.jp.7210842","article-title":"Reflections on Errors in Neonatology: I. The \u201cHands-Off\u201d Years, 1920 to 1950","volume":"23","author":"Robertson","year":"2003","journal-title":"J. Perinatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0002-9394(54)90847-8","article-title":"The incidence and severity of retrolental fibroplasia in relation to possible causative factors*","volume":"38","author":"Zacharias","year":"1954","journal-title":"Am. J. Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0002-9394(42)92088-9","article-title":"Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens","volume":"25","author":"Terry","year":"1942","journal-title":"Am. J. Ophthalmol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jama.1945.02860250028007","article-title":"Ocular maldevelopment in extremely premature infants","volume":"128","author":"Terry","year":"1945","journal-title":"J. Am. Med. Assoc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/S0002-9394(49)90802-8","article-title":"Retrolental Fibroplasia in Premature Infants*: II. Studies on the Prophylaxis of the Disease: The use of Alpha Tocopheryl Acetate","volume":"32","author":"Owens","year":"1949","journal-title":"Am. J. Ophthalmol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9394(51)91923-X","article-title":"Retrolental fibroplasia","volume":"34","author":"Reese","year":"1951","journal-title":"Am. J. Ophthalmol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005). The international classification of retinopathy of prematurity revisited. Arch. Ophthalmol., 123, 991\u2013999.","DOI":"10.1001\/archopht.123.7.991"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"The Committee for the Classification of Retinopathy of Prematurity (1984). An international classification of retinopathy of prematurity. Arch. Ophthalmol., 102, 1130\u20131134.","DOI":"10.1001\/archopht.1984.01040030908011"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0002-9394(52)90001-9","article-title":"Retrolental fibroplasia; etiology and prophylaxis","volume":"35","author":"Szewczyk","year":"1952","journal-title":"Am. J. Ophthalmol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0002-9394(52)90002-0","article-title":"Congenital malformations of the eye induced in mice by maternal anoxia; with particular reference to the problem of retrolental fibroplasia in man","volume":"35","author":"Ingalls","year":"1952","journal-title":"Am. J. Ophthalmol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5694\/j.1326-5377.1951.tb109040.x","article-title":"Intensive oxygen therapy as a possible cause of retrolental fibroplasia: A clinical approach","volume":"2","author":"Campbell","year":"1951","journal-title":"Med. J. Aust."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/archopht.1952.00920010710005","article-title":"Incidence of retrolental fibroplasia in a New York nursery","volume":"48","author":"Silverman","year":"1952","journal-title":"Arch. Ophthalmol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jama.1954.03690210001001","article-title":"Retrolental fibroplasia and oxygen therapy","volume":"155","author":"Lanman","year":"1954","journal-title":"J. Am. Med. Assoc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/0002-9394(52)91140-9","article-title":"Studies on the Effect of High Oxygen Administration in Retrolental Fibroplasia*","volume":"35","author":"Patz","year":"1952","journal-title":"Am. J. Ophthalmol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1542\/peds.72.2.159","article-title":"Retinopathy of prematurity: Incidence and risk factors","volume":"72","author":"Shohat","year":"1983","journal-title":"Pediatrics"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1542\/peds.79.5.663","article-title":"Influence of transcutaneous oxygen monitoring on the incidence of retinopathy of prematurity","volume":"79","author":"Bancalari","year":"1987","journal-title":"Pediatrics"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1542\/peds.60.5.655","article-title":"PaO2 levels and retrolental fibroplasia: A report of the cooperative study","volume":"60","author":"Kinsey","year":"1977","journal-title":"Pediatrics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0161-6420(87)33400-1","article-title":"Retinopathy of prematurity: A randomized, prospective trial of transcutaneous oxygen monitoring","volume":"94","author":"Flynn","year":"1987","journal-title":"Ophthalmology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1542\/peds.79.4.524","article-title":"Pulse oximetry: An alternative method for the assessment of oxygenation in newborn infants","volume":"79","author":"Jennis","year":"1987","journal-title":"Pediatrics"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02442476","article-title":"Spectrophotometric monitoring of arterial oxygen saturation in the fingertip","volume":"18","author":"Yoshiya","year":"1980","journal-title":"Med. Biol. Eng. Comput."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/adc.62.9.882","article-title":"Pulse oximeter and transcutaneous arterial oxygen measurements in neonatal and paediatric intensive care","volume":"62","author":"Southall","year":"1987","journal-title":"Arch. Dis. Child."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1056\/NEJM199204163261603","article-title":"A Cohort Study of Transcutaneous Oxygen Tension and the Incidence and Severity of Retinopathy of Prematurity","volume":"326","author":"Flynn","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1001\/jama.2013.5555","article-title":"Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: A randomized clinical trial","volume":"309","author":"Schmidt","year":"2013","journal-title":"JAMA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1542\/peds.105.2.295","article-title":"Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes","volume":"105","author":"Phelps","year":"2000","journal-title":"Pediatrics"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa0911781","article-title":"Target ranges of oxygen saturation in extremely preterm infants","volume":"362","author":"Schaapveld","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1056\/NEJMoa023080","article-title":"Oxygen-Saturation Targets and Outcomes in Extremely Preterm Infants","volume":"349","author":"Askie","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1056\/NEJMoa1302298","article-title":"Oxygen Saturation and Outcomes in Preterm Infants","volume":"368","author":"Stenson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJMoa1514212","article-title":"Outcomes of two trials of oxygen-saturation targets in preterm infants","volume":"374","author":"Stenson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1001\/jama.2018.5725","article-title":"Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration","volume":"319","author":"Askie","year":"2018","journal-title":"JAMA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000499361","article-title":"European Consensus Guidelines on the Management of Respiratory Distress Syndrome\u20142019 Update","volume":"115","author":"Sweet","year":"2019","journal-title":"Neonatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e20161576","DOI":"10.1542\/peds.2016-1576","article-title":"Committee on Fetus and Newborn Oxygen Targeting in Extremely Low Birth Weight Infants","volume":"138","author":"Cummings","year":"2016","journal-title":"Pediatrics"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1214533","article-title":"A Trial Comparing Noninvasive Ventilation Strategies in Preterm Infants","volume":"369","author":"Kirpalani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jpeds.2009.09.069","article-title":"Caffeine for Apnea of Prematurity Trial: Benefits May Vary in Subgroups","volume":"156","author":"Davis","year":"2010","journal-title":"J. Pediatr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1056\/NEJMoa0911783","article-title":"Early CPAP versus surfactant in extremely preterm infants","volume":"362","author":"Finer","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/bjo.80.5.420","article-title":"Retinopathy of prematurity in a controlled trial of prophylactic surfactant treatment","volume":"80","author":"Pennefather","year":"1996","journal-title":"Br. J. Ophthalmol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archopht.1956.00930040489001","article-title":"Retrolental Fibroplasia","volume":"56","author":"Kinsey","year":"1956","journal-title":"A.M.A. Arch. Ophthalmol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1542\/peds.73.1.82","article-title":"A reexamination of the role of oxygen in retrolental fibroplasia","volume":"73","author":"Lucey","year":"1984","journal-title":"Pediatrics"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/bjo.38.7.397","article-title":"Effect of Oxygen on Developing Retinal Vessels with Particular Reference to the Problem of Retrolental Fibroplasia","volume":"38","author":"Ashton","year":"1954","journal-title":"Br. J. Ophthalmol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9394(57)90426-9","article-title":"Retinal Vascularization in Health and Disease","volume":"44","author":"Ashton","year":"1957","journal-title":"Am. J. Ophthalmol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(64)93051-X","article-title":"High oxygen pressureand the retinal blood-vessels","volume":"2","author":"Dollery","year":"1964","journal-title":"Lancet"},{"key":"ref_92","first-page":"588","article-title":"Oxygen supply to the retina from the retinal and choroidal circulations at normal and increased arterial oxygen tensions","volume":"8","author":"Dollery","year":"1969","journal-title":"Investig. Ophthalmol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S0952523805224112","article-title":"Photoreceptors in the rat retina are specifically vulnerable to both hypoxia and hyperoxia","volume":"22","author":"Wellard","year":"2005","journal-title":"Vis. Neurosci."},{"key":"ref_94","first-page":"168","article-title":"Rod photoreceptors in infant rats with a history of oxygen exposure","volume":"40","author":"Fulton","year":"1999","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_95","first-page":"257","article-title":"Long-term evaluation of retinal morphology and function in a mouse model of oxygen-induced retinopathy","volume":"26","author":"Macke","year":"2020","journal-title":"Mol. Vis"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Smith","year":"2013","journal-title":"Lancet"},{"key":"ref_97","first-page":"126","article-title":"Oxygen-induced retinopathy in newborn kittens. A model for ischemic vasoproliferative retinopathy","volume":"28","author":"Kremer","year":"1987","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1203\/00006450-198807000-00024","article-title":"Reduced Severity of Oxygen-Induced Retinopathy in Kittens Recovered in 28% Oxygen","volume":"24","author":"Phelps","year":"1988","journal-title":"Pediatr. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1203\/00006450-198109000-00013","article-title":"Retrolental Fibroplasia: Evidence for a Role of the Prostaglandin Cascade in the Pathogenesis of Oxygen-Induced Retinopathy in the Newborn Beagle","volume":"15","author":"Flower","year":"1981","journal-title":"Pediatr. Res."},{"key":"ref_100","first-page":"300","article-title":"Vaso-obliteration in the canine model of oxygen-induced retinopathy","volume":"37","author":"McLeod","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_101","first-page":"1322","article-title":"Vasoproliferation in the neonatal dog model of oxygen-induced retinopathy","volume":"37","author":"McLeod","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_102","first-page":"1918","article-title":"Clinical and histopathologic features of canine oxygen-induced proliferative retinopathy","volume":"39","author":"McLeod","year":"1998","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1203\/00006450-199412000-00007","article-title":"Exposure to Alternating Hypoxia and Hyperoxia Causes Severe Proliferative Retinopathy in the Newborn Rat","volume":"36","author":"Penn","year":"1994","journal-title":"Pediatr. Res."},{"key":"ref_104","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"Smith","year":"1994","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/nprot.2009.187","article-title":"Quantification of oxygen-induced retinopathy in the mouse: A model of vessel loss, vessel regrowth and pathological angiogenesis","volume":"4","author":"Connor","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0002-9394(54)90845-4","article-title":"Oxygen Studies in Retrolental Fibroplasia","volume":"38","author":"Patz","year":"1954","journal-title":"Am. J. Ophthalmol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bjo.45.5.321","article-title":"Studies on developing retinal vessels VIII. Effect of oxygen on the retinal vessels of the ratling","volume":"45","author":"Ashton","year":"1961","journal-title":"Br. J. Ophthalmol."},{"key":"ref_108","first-page":"576","article-title":"Variable oxygen exposure causes preretinal neovascularization in the newborn rat","volume":"34","author":"Penn","year":"1993","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1083\/JCB1853OIA6","article-title":"M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis","volume":"185","author":"Kubota","year":"2009","journal-title":"J. Cell Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0161-6420(86)33680-7","article-title":"Cryotherapy for Active Retinopathy of Prematurity","volume":"93","author":"Tasman","year":"1986","journal-title":"Ophthalmology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1136\/bjo.64.10.758","article-title":"Treatment of acute retrolental fibroplasia by cryopexy","volume":"64","author":"Nissenkorn","year":"1980","journal-title":"Br. J. Ophthalmol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988). Multicenter trial of cryotherapy for retinopathy of prematurity: Preliminary results. Pediatrics, 81, 697\u2013706.","DOI":"10.1542\/peds.81.5.697"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (2001). Multicenter trial of cryotherapy for retinopathy of prematurity: Ophthalmological outcomes at 10 years. Arch. Ophthalmol., 119, 1110\u20131118.","DOI":"10.1001\/archopht.119.8.1110"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0161-6420(01)00540-1","article-title":"The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP)","volume":"108","author":"Good","year":"2001","journal-title":"Ophthalmology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ophtha.2012.01.003","article-title":"Current role of cryotherapy in retinopathy of prematurity: A report by the American academy of ophthalmology","volume":"119","author":"Simpson","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0161-6420(91)32247-4","article-title":"Laser Photocoagulation for Stage 3+ Retinopathy of Prematurity","volume":"98","author":"McNamara","year":"1991","journal-title":"Ophthalmology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0161-6420(97)30034-7","article-title":"Early treatment of posterior retinopathy of prematurity: A controlled trial","volume":"104","author":"Vander","year":"1997","journal-title":"Ophthalmology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1001\/archopht.1992.01080240054029","article-title":"Diode laser photocoagulation for retinopathy of prematurity: Preliminary results","volume":"110","author":"McNamara","year":"1992","journal-title":"Arch. Ophthalmol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/archopht.1992.01080130046024","article-title":"Treatment of Retinopathy of Prematurity with Argon Laser Photocoagulation","volume":"110","author":"Landers","year":"1992","journal-title":"Arch. Ophthalmol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0002-9394(01)00956-4","article-title":"Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: Seven-year outcome","volume":"132","author":"Shalev","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0161-6420(01)01017-X","article-title":"A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years","volume":"109","author":"Ng","year":"2002","journal-title":"Ophthalmology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0161-6420(01)01015-6","article-title":"A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: Part 2. Refractive outcome","volume":"109","author":"Connolly","year":"2002","journal-title":"Ophthalmology"},{"key":"ref_123","first-page":"233","article-title":"Early treatment for retinopathy of prematurity cooperative group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1542\/peds.109.1.12","article-title":"Long-Term Ophthalmic Outcome of Low Birth Weight Children with and Without Retinopathy of Prematurity","volume":"109","author":"Stephenson","year":"2002","journal-title":"Pediatrics"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bjo.81.1.2","article-title":"Myopia of prematurity: Nature, nurture, or disease?","volume":"81","author":"Fielder","year":"1997","journal-title":"Br. J. Ophthalmol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10103-011-1021-z","article-title":"Laser treatment for retinopathy of prematurity","volume":"28","author":"Houston","year":"2013","journal-title":"Lasers Med. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1111\/aos.12053","article-title":"Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age","volume":"91","author":"Yang","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid","volume":"219","author":"Senger","year":"1983","journal-title":"Science"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","article-title":"Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells","volume":"161","author":"Ferrara","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vascular permeability factor, an endothelial cell mitogen related to PDGF","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.ophtha.2009.04.026","article-title":"Simultaneous Analyses of Vitreous Levels of 27 Cytokines in Eyes with Retinopathy of Prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"19761","DOI":"10.1074\/jbc.270.34.19761","article-title":"Hypoxia-induced Transcriptional Activation and Increased mRNA Stability of Vascular Endothelial Growth Factor in C6 Glioma Cells","volume":"270","author":"Ikeda","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1042\/bj3270419","article-title":"Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells","volume":"327","author":"Damert","year":"1997","journal-title":"Biochem. J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1074\/jbc.270.3.1230","article-title":"Purification and Characterization of Hypoxia-inducible Factor 1","volume":"270","author":"Wang","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.1147949","article-title":"Life with Oxygen","volume":"318","author":"Semenza","year":"2007","journal-title":"Science"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm0603-677","article-title":"Regulation of angiogenesis by hypoxia: Role of the HIF system","volume":"9","author":"Pugh","year":"2003","journal-title":"Nat. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in Signaling and Disease: Beyond Discovery and Development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular Endothelial Growth Factor: Basic Science and Clinical Progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.yexcr.2005.11.012","article-title":"Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis","volume":"312","author":"Shibuya","year":"2006","journal-title":"Exp. Cell Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s001099900019","article-title":"Molecular and biological properties of vascular endothelial growth factor","volume":"77","author":"Ferrara","year":"1999","journal-title":"J. Mol. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/0002-9378(89)90770-9","article-title":"Blood gases, pH, and lactate in appropriate- and small-for-gestational-age fetuses","volume":"161","author":"Nicolaides","year":"1989","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1523\/JNEUROSCI.15-07-04738.1995","article-title":"Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia","volume":"15","author":"Stone","year":"1995","journal-title":"J. Neurosci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"E2516","DOI":"10.1073\/pnas.1523005113","article-title":"Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity","volume":"113","author":"Hoppe","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: A pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Chan","year":"2008","journal-title":"Retina"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity","volume":"364","author":"Kennedy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of Prematurity","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive Outcomes Following Bevacizumab Monotherapy Compared with Conventional Laser Treatment","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00006982-200404000-00015","article-title":"Contemporary understanding and management of retinopathy of prematurity","volume":"24","author":"Recchia","year":"2004","journal-title":"Retina"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A dosing study of bevacizumab for retinopathy of prematurity: Late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"The Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"ref_160","first-page":"1","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: A prospective case-control study","volume":"4","author":"Fan","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3928\/23258160-20190605-01","article-title":"Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP","volume":"50","author":"Rodriguez","year":"2019","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_162","first-page":"a006551","article-title":"Molecular Parallels between Neural and Vascular Development","volume":"3","author":"Eichmann","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/org.6.2.11687","article-title":"VEGF in the nervous system","volume":"6","author":"Rosenstein","year":"2010","journal-title":"Organogenesis"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: Anatomic outcomes and influencing factors","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity","volume":"124","author":"Vanderveen","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/87904","article-title":"Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions","volume":"7","author":"Carmeliet","year":"2001","journal-title":"Nat. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1042\/CS20040370","article-title":"The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions","volume":"109","author":"Takahashi","year":"2005","journal-title":"Clin. Sci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2018","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9394(49)91102-2","article-title":"Retrolental Fibroplasia in Premature Infants*","volume":"32","author":"Owens","year":"1949","journal-title":"Am. J. Ophthalmol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJM198112033052301","article-title":"Retrolental Fibroplasia: Efficacy of Vitamin E in a Double-Blind Clinical Study of Preterm Infants","volume":"305","author":"Hittner","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1542\/peds.79.4.489","article-title":"Tocopherol efficacy and safety for preventing retinopathy of prematurity: A randomized, controlled, double-masked trial","volume":"79","author":"Phelps","year":"1987","journal-title":"Pediatrics"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Brion, L.P., Bell, E.F., and Raghuveer, T.S. (2003). Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst. Rev., CD003665.","DOI":"10.1002\/14651858.CD003665"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0022-3476(97)70031-3","article-title":"Vitamin E prophylaxis to reduce retinopathy of prematurity: A reappraisal of published trials","volume":"131","author":"Raju","year":"1997","journal-title":"J. Pediatr."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0022-3476(89)80149-0","article-title":"Effect of sustained pharmacologic vitamin E levels on incidence and severity of retinopathy of prematurity: A controlled clinical trial","volume":"114","author":"Johnson","year":"1989","journal-title":"J. Pediatr."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1542\/peds.73.3.387","article-title":"Vitamin E and necrotizing enterocolitis","volume":"73","author":"Finer","year":"1984","journal-title":"Pediatrics"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"C546","DOI":"10.1152\/ajpcell.00424.2002","article-title":"Hyperoxia induces retinal vascular endothelial cell apoptosis through formation of peroxynitrite","volume":"285","author":"Gu","year":"2003","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/nm.2846","article-title":"Pathological neoangiogenesis depends on oxidative stress regulation by ATM","volume":"18","author":"Okuno","year":"2012","journal-title":"Nat. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2010-05-286963","article-title":"Granulocyte colony-stimulating factor attenuates oxidative stress\u2013induced apoptosis in vascular endothelial cells and exhibits functional and morphologic protective effect in oxygen-induced retinopathy","volume":"117","author":"Kojima","year":"2011","journal-title":"Blood"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2013-09-512749","article-title":"Oxidative stress in angiogenesis and vascular disease","volume":"123","author":"Kim","year":"2014","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1442-200X.2008.02662.x","article-title":"Anti-oxidant enzymes and related elements in term and preterm newborns","volume":"51","author":"Nassi","year":"2009","journal-title":"Pediatr. Int."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1067\/mob.2003.357","article-title":"Beneficial impact of term labor: Nonenzymatic antioxidant reserve in the human fetus","volume":"189","author":"Buhimschi","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/eye.1992.43","article-title":"Vitamin E therapy in retinopathy of prematurity","volume":"6","author":"Muller","year":"1992","journal-title":"Eye"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Soghier, L.M., and Brion, L.P. (2006). Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates. Cochrane Database Syst. Rev., CD004869.","DOI":"10.1002\/14651858.CD004869.pub2"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"025","DOI":"10.1055\/s-0032-1321494","article-title":"Lutein and Zeaxanthin Supplementation in Preterm Very Low-Birth-Weight Neonates in Neonatal Intensive Care Units: A Multicenter Randomized Controlled Trial","volume":"30","author":"Manzoni","year":"2012","journal-title":"Am. J. Perinatol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJM199805283382202","article-title":"Lack of Efficacy of Light Reduction in Preventing Retinopathy of Prematurity","volume":"338","author":"Reynolds","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_188","first-page":"CD001073","article-title":"D-Penicillamine for preventing retinopathy of prematurity in preterm infants","volume":"2013","author":"Qureshi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/j.1651-2227.2010.01837.x","article-title":"Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: A randomized, placebo-controlled trial","volume":"99","author":"Tandon","year":"2010","journal-title":"Acta Paediatr."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000336639","article-title":"Reduction of Retinopathy of Prematurity in Extremely Low Gestational Age Newborns Treated with Recombinant Human Cu\/Zn Superoxide Dismutase","volume":"102","author":"Parad","year":"2012","journal-title":"Neonatology"},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Beharry, K.D., Cai, C.L., Siddiqui, F., Chowdhury, S., D\u2019Agrosa, C., Valencia, G.B., and Aranda, J.V. (2018). Comparative Effects of Coenzyme Q10 or n-3 Polyunsaturated Fatty Acid Supplementation on Retinal Angiogenesis in a Rat Model of Oxygen-Induced Retinopathy. Antioxidants, 7.","DOI":"10.3390\/antiox7110160"},{"key":"ref_192","first-page":"291","article-title":"Clinical Efficacy of Topical CoQ10 and Vitamin-E Eye-drop in Retinopathy of Prematurity","volume":"8","author":"Akdogan","year":"2019","journal-title":"Med. Hypothesis. Discov. Innov. Ophthalmol."},{"key":"ref_193","first-page":"270","article-title":"Superoxide Dismutase and Glutathione Peroxidase Content of Human Milk from Mothers of Premature and Full-Term Infants During the First 3 Months of Lactation","volume":"31","author":"Friel","year":"2000","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1203\/00006450-200205000-00012","article-title":"Milk from Mothers of Both Premature and Full-Term Infants Provides Better Antioxidant Protection than Does Infant Formula","volume":"51","author":"Friel","year":"2002","journal-title":"Pediatr. Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/adc.2004.057547","article-title":"Vitamin A and preterm infants: What we know, what we don\u2019t know, and what we need to know","volume":"90","author":"Mactier","year":"2005","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1203\/00006450-198509000-00003","article-title":"Liver Vitamin A Reserves of Very Low Birth Weight Neonates","volume":"19","author":"Shenai","year":"1985","journal-title":"Pediatr. Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0022-3476(81)80484-2","article-title":"Plasma vitamin A and retinol-binding protein in premature and term neonates","volume":"99","author":"Shenai","year":"1981","journal-title":"J. Pediatr."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13052-020-00837-0","article-title":"Oral vitamin A supplementation for ROP prevention in VLBW preterm infants","volume":"46","author":"Garofoli","year":"2020","journal-title":"Ital. J. Pediatr."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1097\/IAE.0000000000002543","article-title":"Early vitamin a supplementation improves the outcome of retinopathy of prematurity in extremely preterm infants","volume":"40","author":"Sun","year":"2020","journal-title":"Retina"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0098-2997(03)00039-6","article-title":"Importance of vitamin-A for lung function and development","volume":"24","author":"Biesalski","year":"2003","journal-title":"Mol. Asp. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1056\/NEJM199906243402505","article-title":"Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants","volume":"340","author":"Tyson","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0022-3476(87)80086-0","article-title":"Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia","volume":"111","author":"Shenai","year":"1987","journal-title":"J. Pediatr."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Araki, S., Kato, S., Namba, F., and Ota, E. (2018). Vitamin A to prevent bronchopulmonary dysplasia in extremely low birth weight infants: A systematic review and meta-analysis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207730"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.pedneo.2013.12.002","article-title":"Effectiveness of Vitamin A in the Prevention of Complications of Prematurity","volume":"55","year":"2014","journal-title":"Pediatr. Neonatol."},{"key":"ref_205","first-page":"476","article-title":"Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells","volume":"74","author":"Lingen","year":"1996","journal-title":"Lab. Investig."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.mce.2006.10.009","article-title":"Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells","volume":"264","author":"Hoffmann","year":"2007","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_207","first-page":"267","article-title":"Inhibition of vascular endothelial growth factor-induced retinal neovascularization by retinoic acid in experimental retinopathy of prematurity","volume":"55","author":"Ozkan","year":"2005","journal-title":"Physiol. Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/mvre.2000.2246","article-title":"Retinoic Acid Selectively Inhibits the Vascular Permeabilizing Effect of VPF\/VEGF, an Early Step in the Angiogenic Cascade","volume":"60","author":"Pal","year":"2000","journal-title":"Microvasc. Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/archopht.1952.01700030565001","article-title":"Results of use of corticotropin (ACTH) in treatment of retrolental fibroplasia","volume":"47","author":"Reese","year":"1952","journal-title":"Arch. Ophthalmol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jama.1995.03520290065031","article-title":"Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH consensus development panel on the effect of corticosteroids for fetal maturation on perinatal outcomes","volume":"273","author":"Gilstrap","year":"1995","journal-title":"JAMA"},{"key":"ref_211","first-page":"378","article-title":"Developmental and Functional Biology of the Primate Fetal Adrenal Cortex","volume":"18","author":"Mesiano","year":"1997","journal-title":"Endocr. Rev."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/jp.2008.190","article-title":"ACTH and cortisol response to critical illness in term and late preterm newborns","volume":"28","author":"Fernandez","year":"2008","journal-title":"J. Perinatol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/cen.12049","article-title":"Limited response to CRH stimulation tests at 2 weeks of age in preterm infants born at less than 30 weeks of gestational age","volume":"78","author":"Niwa","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/ped.13242","article-title":"Late-onset circulatory collapse of prematurity","volume":"59","author":"Kawai","year":"2017","journal-title":"Pediatr. Int."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jsbmb.2004.12.046","article-title":"Gene regulation by the glucocorticoid receptor: Structure:function relationship","volume":"94","author":"Kumar","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0092-8674(90)90395-U","article-title":"Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos\/Jun) activity by glucocorticoid hormone","volume":"62","author":"Jonat","year":"1990","journal-title":"Cell"},{"key":"ref_217","first-page":"408","article-title":"The role of glucocorticoid receptor and gene expression in the anti-inflammatory action of dexamethasone","volume":"280","author":"Tsurufuji","year":"1979","journal-title":"Nat. Cell Biol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1194\/jlr.M800410-JLR200","article-title":"Scavenger receptor class B type I-mediated uptake of serum cholesterol is essential for optimal adrenal glucocorticoid production","volume":"50","author":"Hoekstra","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_219","first-page":"75","article-title":"Retinopathy of prematurity and antenatal corticosteroids. The Italian ROP Study Group","volume":"68","author":"Console","year":"1997","journal-title":"Acta. Biomed. Ateneo. Parm."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archopht.116.5.601","article-title":"Antenatal dexamethasone and decreased severity of retinopathy of prematurity","volume":"116","author":"Higgins","year":"1998","journal-title":"Arch. Ophthalmol."},{"key":"ref_221","first-page":"CD001145","article-title":"Late (>7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants","volume":"10","author":"Doyle","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_222","first-page":"CD001146","article-title":"Early (<8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants","volume":"10","author":"Doyle","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(16)00202-6","article-title":"Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): A double-blind, placebo-controlled, multicentre, randomised trial","volume":"387","author":"Baud","year":"2016","journal-title":"Lancet"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physrev.1992.72.2.449","article-title":"Erythropoietin: Structure, control of production, and function","volume":"72","author":"Jelkmann","year":"1992","journal-title":"Physiol. Rev."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1056\/NEJMoa041773","article-title":"Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy","volume":"353","author":"Watanabe","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_226","first-page":"5447","article-title":"A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol. Cell. Biol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ymthe.2004.07.027","article-title":"Systemic but not intraocular Epo Gene Transfer Protects the Retina from Light-and Genetic-Induced Degeneration","volume":"10","author":"Rex","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.1073\/pnas.152321399","article-title":"Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury","volume":"99","author":"Junk","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1073\/pnas.87.15.5978","article-title":"Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells","volume":"87","author":"Anagnostou","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_230","first-page":"526","article-title":"Erythropoietin deficiency decreases vascular stability in mice","volume":"118","author":"Chen","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1167\/iovs.08-2521","article-title":"Suppression of Retinal Neovascularization by Erythropoietin siRNA in a Mouse Model of Proliferative Retinopathy","volume":"50","author":"Chen","year":"2009","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ajpath.2013.12.023","article-title":"VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis","volume":"184","author":"Yang","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaapos.2007.08.009","article-title":"Human recombinant erythropoietin and the incidence of retinopathy of prematurity: A multiple regression model","volume":"12","author":"Suk","year":"2008","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaapos.2005.09.005","article-title":"Association Between Higher Cumulative Doses of Recombinant Erythropoietin and Risk for Retinopathy of Prematurity","volume":"10","author":"Brown","year":"2006","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_235","first-page":"627","article-title":"Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity?","volume":"159","author":"Romagnoli","year":"2000","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1542\/peds.2013-0143","article-title":"A Randomized, Masked, Placebo-Controlled Study of Darbepoetin Alfa in Preterm Infants","volume":"132","author":"Ohls","year":"2013","journal-title":"Pediatrics"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1907423","article-title":"A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants","volume":"382","author":"Juul","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_238","first-page":"CD004863","article-title":"Early erythropoietin for preventing red blood cell transfusion in preterm and\/or low birth weight infants","volume":"26","author":"Ohlsson","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_239","first-page":"CD004868","article-title":"Late erythropoietin for preventing red blood cell transfusion in preterm and\/or low birth weight infants","volume":"23","author":"Aher","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1126\/science.276.5319.1706","article-title":"Essential Role of Growth Hormone in Ischemia-Induced Retinal Neovascularization","volume":"276","author":"Smith","year":"1997","journal-title":"Science"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/70963","article-title":"Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor","volume":"5","author":"Smith","year":"1999","journal-title":"Nat. Med."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1073\/pnas.101113998","article-title":"Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity","volume":"98","author":"Hellstrom","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"10589","DOI":"10.1073\/pnas.0702031104","article-title":"IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth","volume":"104","author":"Chen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/j.1651-2227.2007.00276.x","article-title":"Inflammation at birth and the insulin-like growth factor system in very preterm infants","volume":"96","author":"Cilio","year":"2007","journal-title":"Acta Paediatr. Int. J. Paediatr."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/pr.2012.146","article-title":"Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: Pharmacokinetics and short-term safety","volume":"73","author":"Ley","year":"2013","journal-title":"Pediatr. Res."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbrc.2017.05.067","article-title":"Identification of vitreous proteins in retinopathy of prematurity","volume":"488","author":"Sugioka","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1016\/j.semcancer.2015.01.001","article-title":"Broad targeting of angiogenesis for cancer prevention and therapy","volume":"35","author":"Wang","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1172\/JCI23298","article-title":"Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth","volume":"115","author":"Nakao","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/pr.56.3.3","article-title":"Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition","volume":"56","author":"Simmons","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.intimp.2009.02.003","article-title":"Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis","volume":"9","author":"Hyde","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1203\/00006450-199908000-00010","article-title":"Indomethacin improves oxygen-induced retinopathy in the mouse","volume":"46","author":"Nandgaonkar","year":"1999","journal-title":"Pediatr. Res."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.CIR.0000080735.93327.00","article-title":"Cyclooxygenase-2 in Human and Experimental Ischemic Proliferative Retinopathy","volume":"108","author":"Sennlaub","year":"2003","journal-title":"Circulation"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1167\/iovs.09-3652","article-title":"The Role of PGE2Receptor EP4in Pathologic Ocular Angiogenesis","volume":"50","author":"Yanni","year":"2009","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0022-3476(83)80022-5","article-title":"Effects of indomethacin in premature infants with patent ductus arteriosus: Results of a national collaborative study","volume":"102","author":"Gersony","year":"1983","journal-title":"J. Pediatr."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1542\/peds.82.4.533","article-title":"Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants","volume":"82","author":"Bandstra","year":"1988","journal-title":"Pediatrics"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0002-9394(14)77799-2","article-title":"The Influence of Indomethacin on Retinopathy of Prematurity","volume":"96","author":"Bolling","year":"1983","journal-title":"Am. J. Ophthalmol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM200106283442602","article-title":"Long-Term Effects of Indomethacin Prophylaxis in Extremely-Low-Birth-Weight Infants","volume":"344","author":"Schmidt","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpeds.2008.01.031","article-title":"Increased Indomethacin Dosing for Persistent Patent Ductus Arteriosus in Preterm Infants: A Multicenter, Randomized, Controlled Trial","volume":"153","author":"Jegatheesan","year":"2008","journal-title":"J. Pediatr."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1055\/s-0028-1103515","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial on Intravenous Ibuprofen L-Lysine for the Early Closure of Nonsymptomatic Patent Ductus Arteriosus within 72 Hours of Birth in Extremely Low-Birth-Weight Infants","volume":"26","author":"Aranda","year":"2008","journal-title":"Am. J. Perinatol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jpeds.2018.09.012","article-title":"PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age","volume":"205","author":"Clyman","year":"2019","journal-title":"J. Pediatr."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1651-2227.2000.tb00767.x","article-title":"Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants","volume":"89","author":"Dani","year":"2000","journal-title":"Acta Paediatr."},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Avila-Vazquez, M., Maffrand, R., Sosa, M., Franco, M., De Alvarez, B.V., Cafferata, M.L., and Bergel, E. (2004). Treatment of Retinopathy of Prematurity with topical ketorolac tromethamine: A preliminary study. BMC Pediatr., 4.","DOI":"10.1186\/1471-2431-4-15"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3928\/01913913-20100920-01","article-title":"Effectiveness of Ketorolac Tromethamine in Prevention of Severe Retinopathy of Prematurity","volume":"48","author":"Giannantonio","year":"2010","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.preteyeres.2004.06.002","article-title":"The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina","volume":"24","author":"SanGiovanni","year":"2005","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.plefa.2006.05.012","article-title":"Polyunsaturated fatty acids and inflammation","volume":"75","author":"Calder","year":"2006","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nm1591","article-title":"Increased dietary intake of \u03c9-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis","volume":"13","author":"Connor","year":"2007","journal-title":"Nat. Med."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"69ra12","DOI":"10.1126\/scitranslmed.3001571","article-title":"5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of \u03c9-3 polyunsaturated fatty acids","volume":"3","author":"Sapieha","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.earlhumdev.2013.11.002","article-title":"The influence of fish-oil lipid emulsions on retinopathy of prematurity in very low birth weight infants: A randomized controlled trial","volume":"90","author":"Beken","year":"2014","journal-title":"Early Hum. Dev."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2174\/1381612824666180601094849","article-title":"The Efficacy of Omega-3 Supplement on Prevention of Retinopathy of Prematurity in Premature Infants: A Randomized Double-blinded Controlled trial","volume":"24","author":"Khalesi","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/0148607113499373","article-title":"Fish-oil fat emulsion supplementation reduces the risk of retinopathy in very low birth weight infants: A prospective, randomized study","volume":"38","author":"Pawlik","year":"2014","journal-title":"J. Parenter. Enter. Nutr."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clnesp.2017.04.004","article-title":"Effects of a lipid emulsion containing fish oil on polyunsaturated fatty acid profiles, growth and morbidities in extremely premature infants: A randomized controlled trial","volume":"20","author":"Najm","year":"2017","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/jamaophthalmol.2017.6658","article-title":"Association of retinopathy of prematurity with low levels of arachidonic acid","volume":"136","author":"Najm","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00154877","article-title":"Reduced severity of oxygen-induced retinopathy in the newborn rat after topical administration of timolol maleate\u2014A preliminary study","volume":"77","author":"Ricci","year":"1991","journal-title":"Doc. Ophthalmol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF00183596","article-title":"Oxygen-induced retinopathy in the newborn rat: Effects of hyperbarism and topical administration of timolol maleate","volume":"233","author":"Ricci","year":"1995","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_275","first-page":"4514","article-title":"Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines","volume":"9","author":"Lutgendorf","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for Severe Hemangiomas of Infancy","volume":"358","author":"Hubiche","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1023\/B:AGEN.0000029411.76494.33","article-title":"Norepinephrine Upregulates Vascular Endothelial Growth Factor in Rat Cardiac Myocytes by a Paracrine Mechanism","volume":"6","author":"Weil","year":"2003","journal-title":"Angiogenesis"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"10357","DOI":"10.1158\/0008-5472.CAN-06-2496","article-title":"Norepinephrine Up-regulates the Expression of Vascular Endothelial Growth Factor, Matrix Metalloproteinase (MMP)-2, and MMP-9 in Nasopharyngeal Carcinoma Tumor Cells","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1471-4159.2011.07530.x","article-title":"Antiangiogenic effects of \u03b22-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy","volume":"119","author":"Martini","year":"2011","journal-title":"J. Neurochem."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1167\/iovs.10-5536","article-title":"Role of the Adrenergic System in a Mouse Model of Oxygen-Induced Retinopathy: Antiangiogenic Effects of \u03b2-Adrenoreceptor Blockade","volume":"52","author":"Ristori","year":"2011","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s10792-018-1018-8","article-title":"The efficacy of propranolol in very preterm infants at the risk of retinopathy of prematurity: Which newborn and when?","volume":"39","author":"Ozturk","year":"2018","journal-title":"Int. Ophthalmol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/02713683.2016.1158272","article-title":"The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index","volume":"42","author":"Korkmaz","year":"2016","journal-title":"Curr. Eye Res."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/archdischild-2013-303951","article-title":"Oral propranolol versus placebo for retinopathy of prematurity: A pilot, randomised, double-blind prospective study","volume":"98","author":"Makhoul","year":"2013","journal-title":"Arch. Dis. Child."},{"key":"ref_284","first-page":"499","article-title":"Oral propranolol in early stages of retinopathy of prematurity","volume":"44","author":"Bancalari","year":"2016","journal-title":"J. P\u00e9rinat. Med."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jpeds.2013.07.049","article-title":"Oral Propranolol for Retinopathy of Prematurity: Risks, Safety Concerns, and Perspectives","volume":"163","author":"Filippi","year":"2013","journal-title":"J. Pediatr."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/pr.2016.230","article-title":"Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: A pilot clinical trial","volume":"81","author":"Filippi","year":"2017","journal-title":"Pediatr. Res."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fped.2019.00180","article-title":"Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study","volume":"7","author":"Filippi","year":"2019","journal-title":"Front. Pediatr."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1002\/j.1460-2075.1996.tb00574.x","article-title":"Rho-associated kinase, a novel serine\/threonine kinase, as a putative target for small GTP binding protein Rho","volume":"15","author":"Matsui","year":"1996","journal-title":"EMBO J."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1161\/CIRCULATIONAHA.104.510248","article-title":"Rho-Kinase Inhibitor Improves Increased Vascular Resistance and Impaired Vasodilation of the Forearm in Patients with Heart Failure","volume":"111","author":"Kishi","year":"2005","journal-title":"Circulation"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd1719","article-title":"Rho kinase, a promising drug target for neurological disorders","volume":"4","author":"Mueller","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMoa1712770","article-title":"Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy","volume":"378","author":"Kinoshita","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-07329-y","article-title":"ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: Contribution to diabetic retinopathy","volume":"7","author":"Rothschild","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/02713683.2016.1183030","article-title":"AMA0428, A Potent Rock Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy","volume":"42","author":"Hollanders","year":"2016","journal-title":"Curr. Eye Res."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"17504","DOI":"10.1073\/pnas.0804054105","article-title":"Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target","volume":"105","author":"Kita","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2337\/db19-1121","article-title":"Claudin-5 Redistribution Induced by Inflammation Leads to Anti-VEGF\u2013Resistant Diabetic Macular Edema","volume":"69","author":"Arima","year":"2020","journal-title":"Diabetes"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1167\/iovs.15-17411","article-title":"Vascular Normalization by ROCK Inhibitor: Therapeutic Potential of Ripasudil (K-115) Eye Drop in Retinal Angiogenesis and Hypoxia","volume":"57","author":"Yamaguchi","year":"2016","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.celrep.2015.01.050","article-title":"ROCK-Isoform-Specific Polarization of Macrophages Associated with Age-Related Macular Degeneration","volume":"10","author":"Zandi","year":"2015","journal-title":"Cell Rep."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1167\/iovs.14-16012","article-title":"M2 Macrophages Enhance Pathological Neovascularization in the Mouse Model of Oxygen-Induced Retinopathy","volume":"56","author":"Zhou","year":"2015","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1167\/iovs.11-9119","article-title":"Intravitreal Anti-VEGF Therapy Blocks Inflammatory Cell Infiltration and Re-Entry into the Circulation in Retinal Angiogenesis","volume":"53","author":"Nakao","year":"2012","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1167\/iovs.09-4605","article-title":"Gene Expression Profile of Hyperoxic and Hypoxic Retinas in a Mouse Model of Oxygen-Induced Retinopathy","volume":"51","author":"Ishikawa","year":"2010","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/labinvest.2011.141","article-title":"Bone marrow-derived monocyte lineage cells recruited by MIP-1\u03b2 promote physiological revascularization in mouse model of oxygen-induced retinopathy","volume":"92","author":"Ishikawa","year":"2011","journal-title":"Lab. Investig."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/nm1649","article-title":"Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors","volume":"13","author":"Soucek","year":"2007","journal-title":"Nat. Med."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1074\/jbc.275.8.5545","article-title":"Chymase as a Proangiogenic Factor","volume":"275","author":"Muramatsu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1172\/JCI89893","article-title":"Mast cell hyperactivity underpins the development of oxygen-induced retinopathy","volume":"127","author":"Matsuda","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/aps.2015.73","article-title":"Novel endogenous angiogenesis inhibitors and their therapeutic potential","volume":"36","author":"Rao","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2012-04-422527","article-title":"SOCS3 is an endogenous inhibitor of pathologic angiogenesis","volume":"120","author":"Stahl","year":"2012","journal-title":"Blood"},{"key":"ref_307","first-page":"917","article-title":"A family of cytokine-inducible inhibitors of signalling","volume":"387","author":"Starr","year":"1997","journal-title":"Nat. Cell Biol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"ra94","DOI":"10.1126\/scisignal.aaa8695","article-title":"SOCS3 in retinal neurons and glial cells suppresses VEGF signaling to prevent pathological neovascular growth","volume":"8","author":"Sun","year":"2015","journal-title":"Sci. Signal."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"10401","DOI":"10.1073\/pnas.1504387112","article-title":"Nuclear receptor ROR\u03b1 regulates pathologic retinal angiogenesis by modulating SOCS3-dependent inflammation","volume":"112","author":"Sun","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archopht.116.6.773","article-title":"Development of tearing in preterm and term neonates","volume":"116","author":"Isenberg","year":"1998","journal-title":"Arch. Ophthalmol."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/pde.13725","article-title":"Evidence-based skin care in preterm infants","volume":"36","author":"Kusari","year":"2018","journal-title":"Pediatr. Dermatol."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/archdischild-2019-317399","article-title":"Development of a neonatal adverse event severity scale through a Delphi consensus approach","volume":"104","author":"Salaets","year":"2019","journal-title":"Arch. Dis. Child."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/2\/331\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:12:16Z","timestamp":1760159536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/2\/331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":312,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["jcm10020331"],"URL":"https:\/\/doi.org\/10.3390\/jcm10020331","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,18]]}}}